Lund, Sweden – June 2, 2025 – Fåhraeus Startup & Growth Fund II (FSG) today announces its investment in Atley Solutions, a Swedish company pioneering automated production of astatine-211 radiopharmaceuticals for targeted alpha therapy. The investment was led by FSG and was part of a €5 million funding round, alongside existing investors Chalmers Ventures, Vätterleden and Marinvest.

Atley Solutions is a global leader in commercial products and services for astatine-related pharmaceutical development. Its Atley C100 module is the world’s first commercial system able to both purify astatine-211 from cyclotron targets and synthesise At-211-based radiopharmaceuticals in an automated process, addressing a critical bottleneck in the supply chain for targeted alpha therapy.

“Atley Solutions’ pioneering work in At-211 radiopharmaceutical manufacturing aligns perfectly with our mission to support transformative life science innovations. We’re excited to help build the company and open up new treatment possibilities in targeted alpha therapies,” said Johanna Asklin, General Partner at FSG.

The investment will enable Atley to scale its manufacturing capabilities and support the translation of customers’ At-211 programs into the clinic. These efforts will further strengthen Atley’s position as a leading provider of manufacturing solutions for targeted alpha therapies.  

“We’re pleased to have secured the funding necessary to continue expanding our operations and supporting our customers in the transition toward clinical application. The continued confidence from our existing investors, combined with the partnership of FSG, provides a strong foundation for the next phase of our growth,” said Milton Lönnroth, CEO of Atley Solutions.

About Atley Solutions

Atley Solutions is a Swedish drug-development company specialising in automated, standardised and reproducible production of At-211 radiopharmaceuticals for targeted alpha therapy. Its Atley C100 module is the world’s first commercial system to both purify and synthesise At-211-based radiopharmaceuticals.

About Fåhraeus Startup & Growth (FSG)

Fåhraeus Startup & Growth FSG Fund II (FSG) is a leading Nordic venture capital fund specializing in supporting high-impact startups and growth-stage companies in technology and life sciences. FSG combines strategic investments with deep industry expertise to empower transformative innovations. FSG Fund II is supported by the European Investment Fund (EIF).